Index of Current Clinical Trials

 Listed below are study summaries of the clinical trials SDCRI is presently supporting. (Programs for prostate cancer and brain tumors are under development).

1. Breast Cancer
2. Colorectal Cancer
3. Low Grade Non-Hodgkin's Lymphoma
4. Non-Small Cell Lung Cancer (NSCLC)
5. Prostate Cancer

Non-Small Cell Lung Cancer (NSCLC)

1. An Open Label, Randomized, Phase II study to Determine Hemoglobin Dose Response Patients with Stage IIIB and IV Non-Small Cell Lung Cancer

Target Patient Population:
· Patients with Stage IIIB or IV NSCLC who are receiving chemotherapy treatment
· Patients must be receiving first or second line chemotherapy treatment
· Patients must have at least 12 weeks of chemotherapy remaining
· Patient must be anemic

Patients who are already receiving treatment for their lung cancer and become anemic would be randomized to one of two treatment groups. One group receives treatment every week and the other group received treatment every 3 weeks. All patients receive treatment for their anemia. The drug is a new agent that is not approved by the FDA. . This is an open label study, therefore all patients will know which group they have been assigned.

Please contact Christine DeFrancisco at 760-598-1700 for more details.

2. A Phase II Ramdomized Study Comparing 2 Combinations of Chemotherapy, With or Without a Study Medication

Target Patient Population:
· Patients with relapse Non-Small Cell Lung Cancer (NSCLC)
· Patients must have received one prior chemotherapy treatment
· Patients must have stage IIIB or IV disease

Patients will be randomized to receive one of 2 standard chemotherapy treatments. Each treatment group will also be randomized to either receive study medication or no study medication. This is an open label study, therefore all patients will know which group they have been assigned.

Please contact Dawn Billingsley at 760-598-1700 for more details.

3. An Open Label Study Using Chemotherapy Plus Radiation Therapy Followed by Additional Chemotherapy

Target Patient Population:
· Patients must have stage IIIA or IIIB Non-Small Cell Lung Cancer
· Patients must be previously untreated with Chemotherapy or radiation therapy
· Patients must be eligible for radiation therapy as defined by his or her physician

Patient will receive one of 2 different doses of chemotherapy in addition to radiation therapy. The radiation therapy will be followed by an additional 3 cycles of chemotherapy.

Please contact Christine DeFrancisco at 760-598-1700 for more details.

Small Cell Lung Cancer

1. An Open Label Study Comparing Two Different Standard Chemotherapy Regimens combined with a Novel New Chemotherapy Agent in Patients with Small Cell Lung Cancer

Target Patient Population:
· Patients must have extensive small cell lung cancer at diagnosis
· Patients must be previously untreated with chemotherapy

All patients will receive the study drug (which is an anti-folate metabolite) with one of two chemotherapies.

Please contact Christine DeFrancisco at 760-598-1700 for more details.